Drug Details
General Information of the Drug (ID: DR1480) | ||||
---|---|---|---|---|
Name |
Parecoxib
|
|||
Synonyms |
Parecoxib; 198470-84-7; Dynastat; SC-69124; SC 69124; CHEBI:73038; UNII-9TUW81Y3CE; N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamide; 9TUW81Y3CE; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylpropanamide; N-[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonyl]propanamide; Propanamide, N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-; Valus-P; Vorth-P; Parocoxib; Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-; N-{[4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonyl}propanamide; parecoxibum; Parecoxib [USAN:INN:BAN]; Valdecoxib Impurity J; Parecoxib (USAN/INN); SCHEMBL9529; GTPL2895; CHEMBL1206690; DTXSID1044229; HMS3741C09; HMS3885L14; AMY42103; BCP07254; EX-A1993; ZINC5761797; BDBM50506744; CP0130; s4656; AKOS025401810; CCG-268299; CS-1959; DB08439; SC69124; NCGC00181773-03; NCGC00181773-05; NCGC00378576-02; Parecoxib 100 microg/mL in Acetonitrile; AC-25842; AS-72353; HY-17474; FT-0697932; Y1120; Parecoxib, VETRANAL(TM), analytical standard; D03716; Q347941; J-523329; BRD-K13800121-236-01-7; N-[4-(5-Methyl-3-phenyl-oxazol-4-yl)phenyl]sulfonylpropanamde; n-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]-propanamide; n-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide; N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl}propanamide; N-[[4-(5-methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide; N-?[[4-?(5-?Methyl-?3-?phenyl-?4-?isoxazolyl)?phenyl]?sulfonyl]?propanamide; PXB
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Gastrointestinal stromal tumor [ICD-11: 2B5B] | Phase 4 | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C19H18N2O4S
|
|||
PubChem CID | ||||
Canonical SMILES |
CCC(=O)NS(=O)(=O)C1=CC=C(C=C1)C2=C(ON=C2C3=CC=CC=C3)C
|
|||
InChI |
1S/C19H18N2O4S/c1-3-17(22)21-26(23,24)16-11-9-14(10-12-16)18-13(2)25-20-19(18)15-7-5-4-6-8-15/h4-12H,3H2,1-2H3,(H,21,22)
|
|||
InChIKey |
TZRHLKRLEZJVIJ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 198470-84-7
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Phloroglucinol | Dryopteris arguta | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Experimental
Result(s) |
Parecoxib in combination with phloroglucinol for acute renal colic has a faster action, also reduces the demand of rescue analgesics. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Lactotransferrin (LTF) | Molecule Info | [3] | |
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | Click to Show/Hide | ||
2 | TCR Signaling Pathway | |||
Reactome | ROS production in response to bacteria | Click to Show/Hide | ||
2 | Amyloid formation | |||
WikiPathways | Latent infection of Homo sapiens with Mycobacterium tuberculosis | Click to Show/Hide |
